374 TERT Expression Predicts Progression-Free Survival in Meningiomas Independent of TERT Promoter Mutation

View at publisher Summarise with VIRAT
Authors: Chloe Gui, Justin Z. Wang, Vikas Patil, Alexander Landry, Olivia Singh, Pedro Castelo-Branco, Uri Y. Tabori, Kenneth Aldape, Felix Behling, Jill S. Barnholtz‐Sloan, Craig Horbinski, Ghazaleh Tabatabai
+18 more Andrew A. Ajisebutu, Jeff Liu, Zeel Patel, Rebeca Yakubov, Ramneet Kaloti, Yosef Ellenbogen, Christopher Wilson, Aaron Cohen‐Gadol, Marcos S. Tatagiba, Eric C. Holland, Andrew Edward Sloan, Silky Chotai, Lola Blackwell Chambless, Andrew F. Gao, Serge Makarenko, Stephen Yip, Farshad Nassiri, Gelareh Mohammed Zadeh
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: While TERT promoter mutation (TPM) has been established as a marker of clinically aggressive meningiomas, this alteration is rare and found in less than 5% of all cases. However, there may be a much larger proportion of meningiomas with aberrant TERT expression despite not having a TPM (TP-WT). The clinical significance of this as a biomarker has not been previously explored in meningiomas. METHODS: Clinical and molecular data were retrospectively collected on 1241 meningiomas, split into a Toronto discovery cohort and a multi-institutional validation cohort. Sanger sequencing and bulk RNA sequencing were used to determine TPM status and TERT gene expression. The effect of TERT expression on progression-free survival (PFS) was assessed using Kaplan-Meier and Cox regression analysis. RESULTS: While meningiomas with TPM showed expectedly higher TERT gene expression compared to TP-WT cases (p < 0.0001), TERT expression was still detected in 28.7% (157/547) of TP-WT meningiomas. Meningiomas with TERT expression showed significantly worse PFS compared to meningiomas without any TERT expression. In fact, WHO grade 1 meningiomas with TERT expression had PFS outcomes resembling WHO grade 2 meningiomas lacking TERT expression (p = 0.59). In turn, WHO grade 2 meningiomas with TERT expression had clinical outcomes similar to WHO grade 3 meningiomas without TERT expression (p = 0.42). Furthermore, the proportion of meningiomas expressing TERT as well as overall TERT expression levels increased with increasing WHO grade. Multivariable analysis showed that TERT expression was significantly associated with worse PFS even when controlling for other known predictors of clinical outcome including TPM, CDKN2A/B loss, 1p/22q status and WHO grade (HR 1.85 [95% CI 1.33-2.57], p = 0.00024). CONCLUSIONS: TERT expression is a novel independent biomarker of outcome for meningiomas identifiable in up to one-third of cases that may be utilized to reclassify tumours to a higher WHO grade.

Fields of Study & Subjects

Meningioma and schwannoma management Bone Tumor Diagnosis and Treatments Pituitary Gland Disorders and Treatments

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
102–102
Publication date
26 March 2026
Language
EN